Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 15;152(6):1060-1068.
doi: 10.1002/ijc.34286. Epub 2022 Oct 10.

Assessing the risk of cervical neoplasia in the post-HPV vaccination era

Matti Lehtinen  1   2 , Ville N Pimenoff  2 , Belinda Nedjai  3 , Karolina Louvanto  1   4 , Lisanne Verhoef  5   6 , Daniëlle A M Heideman  5   6 , Mariam El-Zein  7 , Martin Widschwendter  8   9   10   11 , Joakim Dillner  2
Affiliations
Review

Assessing the risk of cervical neoplasia in the post-HPV vaccination era

Matti Lehtinen et al. Int J Cancer. .

Abstract

This review is based on the recent EUROGIN scientific session: "Assessing risk of cervical cancer in the post-vaccination era," which addressed the demands of cervical intraepithelial neoplasia (CIN)/squamous intraepithelial lesion (SIL) triage now that the prevalence of vaccine-targeted oncogenic high-risk (hr) human papillomaviruses (HPVs) is decreasing. Change in the prevalence distribution of oncogenic HPV types that follows national HPV vaccination programs is setting the stage for loss of positive predictive value of conventional but possibly also new triage modalities. Understanding the contribution of the latter, most notably hypermethylation of cellular and viral genes in a new setting where most oncogenic HPV types are no longer present, requires studies on their performance in vaccinated women with CIN/SIL that are associated with nonvaccine HPV types. Lessons learned from this research may highlight the potential of cervical cells for risk prediction of all women's cancers.

Keywords: cervical cancer; epigenetics; gynecological cancers; human papillomavirus; methylation.

PubMed Disclaimer

Conflict of interest statement

Matti Lehtinen, Ville N. Pimenoff, Belinda Nedjai, Karolina Louvanto, Lisanne Verhoef and Joakim Dillner have no conflicts of interest to declare. Mariam El‐Zein holds a patent related to the discovery “DNA methylation markers for early detection of cervical cancer” registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada (October 2018). Daniëlle A. M. Heideman is minority shareholder of Self‐screen B.V., a spin‐off company of VUmc; Self‐screen B.V. develops, manufactures and licenses high‐risk HPV and methylation marker assays for cervical cancer screening and hold patents of these tests. Martin Widschwendter is a shareholder of Sola Diagnostics GmbH, which holds an exclusive license to the intellectual property that protects the commercialization of the WID‐tests.

Figures

FIGURE 1
FIGURE 1
Community‐level human papillomavirus (HPV) prevalence distribution visualized using ecological β‐diversity analysis among young 18‐year‐old women 4 years after community‐randomized gender‐neutral (A) or girls‐only (B) HPV vaccination, and control communities where hepatitis B‐virus vaccination was implemented (C). Arm A/B communities cluster separately from the control arm C communities mostly due to depletion of vaccine‐targeted HPV types 16/18/31/45 in the intervention A and B communities but also due to differential clustering driven by the not vaccine‐targeted HPV types 51/58/59. White dots represent HPV types community‐level prevalence distribution in two dimensions of the dissimilarity matrix with the blue (A), yellow (C) and gray (C) dots representing each of the 11 communities in each trial arm. The elliptic circles represent the overall diversity among the gender‐neutral (A) or girls‐only (B) HPV vaccinated and control (C) communities, respectively. Original HPVs prevalence data has been previously described by Gray et al and Louvanto et al
FIGURE 2
FIGURE 2
Finnish community and individually‐randomized trial cohorts with population‐based, country‐wide human papillomavirus (HPV) vaccination and cervical screening of 1992 to 1995 birth cohorts since 2007
FIGURE 3
FIGURE 3
Utilizing DNA methylation signatures in easy to access epithelial cell containing cervical smear samples to predict the risk of (screen) all four women cancers
See this image and copyright information in PMC

References

    1. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papilloma virus following a national bivalent human papilloma virus vaccination programme in Scotland: a 7‐year cross‐sectional study. Lancet Infect Dis. 2017;17:1293‐1302. - PubMed
    1. Vänskä S, Luostarinen T, Baussano I, et al. Vaccination with moderate coverage eradicates oncogenic HPV if a gender‐neutral strategy is applied. J Infect Dis. 2020;222:948‐956. - PMC - PubMed
    1. Gray P, Kann H, Pimenoff VN, et al. HPV seroprevalence in pregnant women following gender‐neutral and girls‐only vaccination programs in Finland: a cross‐sectional cohort analysis following a cluster‐randomised trial. PloS Med. 2021;18:e1003588. - PMC - PubMed
    1. Palmer TJ, Wallace L, Pollock KGJ, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12‐13 in Scotland: retrospective population study. BMJ. 2019;365:I1161. - PMC - PubMed
    1. Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in prevalence of human papillomavirus vaccine‐type infection among females after introduction of vaccine — United States, 2003‐2018. MMWR Morb Mortal Wkly Rep. 2021;70:415‐420. - PMC - PubMed

Publication types

MeSH terms

Substances